Publikationen

Im folgenden finden Sie eine Auswahl von Publikationen über PentraSorb^® CRP und zur pathologischen Wirkung von CRP thematisch sortiert.

Kardiovaskulär

• Current Pharmaceutical Design 2023; 8, doi: 10.2174/1381612829666230310090601.
  C-reactive Protein Apheresis in Acute Myocardial Infarction Study
  Milosevic M, Balint B, Ilic I, Dukuljev N, Otasevic P.
• J. Clin. Med. 2022; 11, 6446. doi: 10.3390/jcm11216446.
  Sustainability of C-Reactive Protein Apheresis in Acute Myocardial Infarction—Results from a Supplementary Data Analysis of the Exploratory C-Reactive Protein in Acute Myocardial Infarction-1 Study
  Skarabis H, Torzewski J, Ries W, Heigl F, Garlichs C.D, Kunze R, Sheriff A.
• J. Clin. Med. 2022; 11(4), 1058. doi: 10.3390/jcm11041058.
  C-Reactive Protein (CRP) Blocks the Desensitization of Agonistic Stimulated G Protein Coupled Receptors (GPCRs) in Neonatal Rat Cardiomyocytes.
  Wallukat G, Mattecka S, Wenzel K, Schrödl W, Vogt B, Brunner P, Sheriff A, Kunze R.
  
• Intensiv News. Ausgabe 3/2021; Jahrgang 25: 14-17.
  CRP-Apherese bei Herzinfarkt – eine Therapieoption?.
  Werdan K.
  Veröffentlichung mit freundlicher Genehmigung der Medicom VerlagsgmbH
  
• Nephro News. Ausgabe 2/2021; Jahrgang 23: 23-26.
  CRP-Apherese beim Myokardinfarkt: Eine neue Domäne der Nephrologie?.
  Gauckler P, Mayer G.
  Veröffentlichung mit freundlicher Genehmigung der Medicom VerlagsgmbH
  
• Front Cardiovasc Med. 2021 Mar 8:591714. doi: 10.3389/fcvm.2021.591714.
  C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study
  Ries W, Torzweski J, Heigl F, Pfluecke C, Kelle S, Darius H, Ince H, Mitzner S, Nordbeck P, Butter C, Skarabis H, Sheriff A, Garlichs CD, on behalf of the CAMI-1 Investigators.
  
• Int J Cardiol. 2020 Dec 9;328:191-196. doi: 10.1016/j.ijcard.2020.12.006.
  High sensitivity C-reactive protein is associated with worse infarct healing after revascularized ST-elevation myocardial infarction.
  Tiller C, Reindl M, Holzknecht M, Lechner I, Simma F, Schwaiger J, Mayr A, Klug G, Bauer A, Reinstadler SJ, Metzler B.
  
• Blood Purif. 2020 Feb 28:1-5. doi: 10.1159/000506176.
  A Promising Innovative Treatment for ST-Elevation Myocardial Infarction: The Use of C-Reactive Protein Selective Apheresis: Case Report
  Boljevic D, Nikolic A, Rusovic S, Lakcevic J, Bojic M, Balint B.
  
• Ther Apher Dial. 2019 Dec;23(6):570-574. doi: 10.1111/1744-9987.12804. Epub 2019 Apr 29.
  Selective C-Reactive Protein-Apheresis in Patients.
  Ries W, Heigl F, Garlichs C, Sheriff A, Torzewski J.
  
• Nephro News. Ausgabe 6/2019; Jahrgang 21: 23-27.
  Die CRP-Apherese: Eine neue Therapiemöglichkeit bei Inflammation.
  Ries W.
  Veröffentlichung mit freundlicher Genehmigung der Medicom VerlagsgmbH
  
• Case Rep Cardiol. 2018 Nov 6;2018:4767105. doi: 10.1155/2018/4767105. eCollection 2018.
  “First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction.
  Ries W, Sheriff A, Heigl F, Zimmermann O, Garlichs CD, Torzewski J.
  
• Clin Cardiol. 2018 Jun 27;41(9):1201-1206. doi: 10.1002/clc.23017.
  C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up.
  Vanhaverbeke M, Veltman D., Pattyn N, De Crem N, Gillijns H, Cornelissen V, Janssens S, Sinnaeve PR.
  
• Europ Heart J. 2017 Oct 1;6(7):640–649. doi: 10.1177/2048872616661691.
  Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction.
  Reindl M, Reinstadler SJ, Feistritzer H, Klug G, Tiller C, Mair J, Mayr A, Jaschke W, Metzler B.
  
• Arch Med Sci. 2017 Aug;13(5):1086-1093. doi: 10.5114/aoms.2017.69327. Epub 2017 Aug 3.
  C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty.
  Stumpf C, Sheriff A, Zimmermann S, Schaefauer L, Schlundt C, Raaz D, Garlichs CD, Achenbach S.
  
• BMC Cardiovasc Disord. 2016 Nov 28;16(239). doi: 10.1186/s12872-016-0415-z.
  Multimarker approach for the prediction of microvascular obstruction after acute ST-segment elevation myocardial infarction: a prospective, observational study.
  Feistritzer H, Reinstadler SJ, Klug G, Reindl M, Wöhrer S, Brenner C, Mayr A, Mair J, Metzler B.
  
• J Clin Apher. 2015 Feb;30(1):15-21. doi: 10.1002/jca.21344. Epub 2014 Jul 5.
  Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?
  Sheriff A, Schindler R, Vogt B, Abdel-Aty H, Unger JK, Bock C, Gebauer F, Slagman A, Jerichow T, Mans D, Yapici G, Janelt G, Schröder M, Kunze R, Möckel M.
  
• Blood Purif. 2011;31(1-3):9-17. doi: 10.1159/000320763. Epub 2010 Dec 7.
  Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model.
  Slagman AC, Bock C, Abdel-Aty H, Vogt B, Gebauer F, Janelt G, Wohlgemuth F, Morgenstern R, Yapici G, Puppe A, Modersohn D, Mans D, Jerichow T, Ott S, Kunze R, Schrödl W, Janko C, Hermann M, Kalden JR, Kern P, Parsch H, Kirschfink M, Schulz-Menger J, Röttgen R, Unger JK, Frei U, Schindler R, Möckel M, Sheriff A.
  
• N Engl J Med. 2006 Aug 3;355(5):513-5.
  Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein.
  Kitsis RN, Jialal I.
• Nature. 2006 Apr 27;440(7088):1217-21.
  Targeting C-reactive protein for the treatment of cardiovascular disease.
  Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP.
  
• J Pharmacol Exp Ther. 2002 Dec;303(3):1007-13.
  C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion.
  Barrett TD, Hennan JK, Marks RM, Lucchesi BR.
  
• J Exp Med. 1999 Dec 20;190(12):1733-40.
  C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
  Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB.
  

Grundlagen

Biomedicines 2023, 11(8), 2279. doi: 10.3390/biomedicines.11082279.
Being Eaten Alive: How Energy-Deprived Cells Are Disposed of, Mediated by C-Reactive Protein — Including a Treatment Option
Sheriff A, Kunze R, Brunner P, Vogt B.

Front. Immunol. 2023 Jul 26:1237729. doi: 10.3389/fimmu.2023.1237729.
C-reactive protein: a target for therapy to reduce inflammation
Rizo-Téllez SA, Sekheri M, Filep JG.

J. Clin. Med. 2022; 11(13), 3610. doi: 10.3390/jcm11133610
Special Issue “C-Reactive Protein and Cardiovascular Disease: Clinical Aspects”.
Sheriff A.

Ärzteblatt M-V. 4/2022.
C-reaktives Protein – Entzündungsmarker, Nekrosetrigger und therapeutisches Target.
Kunze R, Espsito F.

J. Clin. Med. 2022; 11,1771. doi: 10.3390/jcm11071771
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons.
Torzewski J, Brunner P, Ries W, Garlichs C D, Kayser S, Heigl F, Sheriff A.

Medizinische Klinik – Intensivmedizin und Notfallmedizin. 2022 Mar 28. doi: 10.1007/s00063-022-00911-x.
CRP-Apherese bei akutem Myokardinfarkt bzw. COVID-19.
Buerke M, Sheriff A, Garlichs C.D.

Front. Immunol. 2021 Feb 12:630430. doi: 10.3389/fimmu.2021.630430.
C-reactive Protein Triggers Cell Death in Ischemic Cells
Sheriff A, Kayer S, Brunner P, Vogt B.

Front. Immunol. 2020 Aug 28:11. doi: 10.3389/fimmu.2020.01978
C-reactive Protein causes Blood Pressure Drop in Rabbits and induces Intracellular Calcium Signaling
Bock C, Vogt B, Mattecka S, Yapici G, Brunner P, Fimpel S, Unger JK, Sheriff A.

Ther Apher Dial. 2019 Dec;23(6):494-496. doi: 10.1111/1744-9987.12802.
C-Reactive Protein: From Biomarker to Trigger of Cell Death?
Kunze, R.

Ther Apher Dial. 2019 Oct;23(5):474-481. doi: 10.1111/1744-9987.12796. Epub 2019 Mar 21.
PentraSorb C-Reactive Protein: Characterization of the Selective C-Reactive Protein Adsorber Resin.
Mattecka S, Brunner P, Hähnel B, Kunze R, Vogt B, Sheriff A.

Front Immunol. 2018 Jun 12;9:1351. doi: 10.3389/fimmu.2018.01351.
Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes.
McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, Peter K.

Circulation 2014 Apr 28;130:35–50. doi: 10.1161/CIRCULATIONAHA.113.007124.
Dissociation of Pentameric to Monomeric C-Reactive Protein Localizes and Aggravates Inflammation.
Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, Bannasch H, Scheichl A, Woollard KJ, Dobschütz E, Kolodgie F, Virmani R, Stark B, Peter K, Eisenhardt SU.

COVID-19

J. Clin. Med. 2022; 11,1956. doi: 10.3390/jcm11071956
Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) Apheresis.
Esposito F, Matthes H, Schad F.

Am J Case Rep. 2021 Dec 30. In Press: DOI: 10.12659/AJCR.935263
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV) Registry.
Schumann C, Heigl F, Rohrbach I, Sheriff A, Wagner L, Wagner F, Torzewski J.

Front. Immunol. 12:708101. doi: 10.3389/fimmu.2021.708101
Case Report: C- Reactive Protein Apheresis in a Patient With COVID-19 and Fulminant CRP Increase.
Ringel J, Ramlow A, Bock C and Sheriff A.

Am J Case Rep. 2021 Jul 27: 22: e932964. doi: 10.12659/AJCR.932964
Successful Treatment of a 39-Year-Old COVID-19 Patient with Respiratory Failure by Selective C-Reactive Protein Apheresis.
Torzewski J, Zimmermann O, Kayser S, Heigl F, Wagner F, Sheriff A, Schumann C.

Eur Heart J. 2021 Mar 29: ehab169, doi: 10.1093/eurheartj/ehab169
C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?.
Pepys MB.

Eur Heart J. 2021 Jan 21: ehaa1103. doi: 10.1093/eurheartj/ehaa1103
C-reactive protein and clinical outcomes in patients with COVID-19.
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS.

Cell Rep Med. 2020 Nov 17: 1;8. doi: 10.1016/j.xcrm.2020.100144
Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients.
Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, Keras G, Penn EH, Massaro AF, Kim EY.

MedPage Today 2020 Jul 27
Apheresis gets Tryout in COVID-19
Kate Kneisel

Am J Case Rep. 2020 Jul 14:21:e925020. doi: 10.12659/AJCR.925020
First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection.
Torzewski J, Heigl F, Zimmermann O, Wagner F, Schumann C, Hettich R, Bock C, Kayser S, Sheriff A.

Ther Apher Dial. 2020 Jun 05. doi: 10.1111/1744-9987.13532
Selective C-reactive protein apheresis for Covid-19 patients suffering from organ damage.
Kayser S, Kunze R, Sheriff A.

Neurologisch

J Clin Med. 2020 Sep; 9(9):2974.
Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations.
Kayser S, Brunner P, Althaus K, Dorst J, Sheriff A.

J Cereb Blood Flow Metab. 2004 Nov; 24(11):1214-8.
Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.
Gill R, Kemp JA, Sabin C, Pepys MB.